Суцираслимаб

Rec. INN (наименование, зарегистрированное ВОЗ)

2415439-63-1

immunoglobulin G1-kappa, anti-[Homo sapiens CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14)], chimeric monoclonal antibody;
gamma1 heavy chain chimeric (1-453) [VH Musmus/Homsap (Mus musculus IGHV5-12-1*01 (96.9%) -(IGHD) -IGHJ3*01 (100%)/Homo sapiens IGHV3-11*01 (79.4%) -(IGHD) -IGHJ4*01 (92.3%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo sapiens IGHG1*03 (100%), G1m3, nG1m1 (CH1 R120 (220) (124-221), hinge 1-15 (222-236), CH2 (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with kappa light chain chimeric (1'-214') [V-KAPPA Musmus/Homsap (Mus musculus IGKV10-96*01 (96.8%) -IGKJ1*01 (100%)/Homo sapiens IGKV1-39*01 (73.7%) -IGKJ4*01 (90.9%) V124>L (104), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (232-232'':235-235'')-bisdisulfide, produced in SP2/0-Ag14 murine myeloma cell line, glycoform alfa

Поделиться этой страницей